Home Newsfeeds HC Wainwright & Co. Downgrades Bionomics to Neutral

HC Wainwright & Co. Downgrades Bionomics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Bionomics (NASDAQ:BNOX) from Buy to Neutral.

byBenzinga Newsdesk

December 19, 2022

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis downgrades Bionomics (NASDAQ:BNOX) from Buy to Neutral.

Analyst Ratings

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts

By Benzinga Insights

May 28, 10:00 AM

Ratings for Apellis Pharmaceuticals (NASDAQ:APLS) were provided by 15 analysts in the past three months, showcasing a mix…

APLS

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet

By Chris Katje

April 27, 4:16 PM

Investors are on the hunt for undervalued, underfollowed and emerging stocks and retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming.

BTC

Weight Loss Drug Competition – FDA Approves Expanded Use Of Eli Lilly’s Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk’s Price

By Vandana Singh

November 8, 3:04 PM

The FDA has approved

LLY

Analyst Ratings

Where Moelis & Co Stands With Analysts

By Benzinga Insights

July 8, 5:01 PM

Over the past 3 months, 4 analysts have published their opinion on Moelis & Co (NYSE:MC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

HC Wainwright & Co. Downgrades Bionomics to Neutral

Related Posts

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet

Weight Loss Drug Competition – FDA Approves Expanded Use Of Eli Lilly’s Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk’s Price

Where Moelis & Co Stands With Analysts